Abstract
Background Tuberculosis (TB) remains a significant public health challenge, particularly in rural areas of high-burden countries like China. Active case finding (ACF) and timely treatment has been proved effective in reducing TB prevalence but it is still unknown regarding the impact on TB epidemic when employing new technologies in ACF. This study aims to evaluate the effectiveness of a comprehensive ACF package utilizing mobile vans equipped with artificial intelligence (AI)-aided radiology, and GeneXpert testing in reducing TB prevalence among high-risk populations in rural Guangxi, China.
Methods A pragmatic cluster randomized controlled trial will be conducted in two counties of Guangxi, China. The trial will randomize 23 townships to intervention or control groups at 1:1 ratio. The intervention group will receive a single ACF campaign in Year 1, incorporating mobile vans, AI-based DR screening, symptom assessment, and sputum collection for GeneXpert testing. Control group participants will receive usual care. TB patients identified in Year 1 will be required to complete TB treatment in Year 2. The primary outcome is the prevalence rate of bacteriologically confirmed TB among high-risk populations in Year 3. Process evaluation will explore adaption, acceptability and feasibility of the intervention. We will conduct incremental costing study to inform future scale-up of the intervention in other settings.
Discussion This study will provide valuable insights into the effectiveness and feasibility of utilizing AI, mobile vans and GeneXpert for TB ACF to reduce TB prevalence in rural settings. If successful, this model will contribute to possible solutions to achieve the WHO End TB Strategy by 2035.
Trial registration: ClinicalTrials.gov Identifier -NCT06702774
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov Identifier -NCT06702774
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has obtained ethical approval from the Guangxi Institutional Review Board of the Guangxi CDC on 26 August 2021 (Ref: GXIRB2021-0033).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing statement
Metadata won’t be publicly available due to local policy. Clustered data can be shared by email (Guangxi CDC, lxy530028{at}163.com) based on reasonable request for research purpose only upon approval after January 1, 2027.
List of abbreviations
- AI
- Artificial Intelligence
- AIDS
- Acquired Immunodeficiency Syndrome
- CDC
- Center for Disease Prevention and Control
- DMC
- Data Monitoring Committee
- DR
- Digital Radiography
- HIV
- Human immunodeficiency Virus
- MDR-TB
- Multidrug-resistant Tuberculosis
- NTP
- National TB Program
- RCT/cRCT
- Randomised Controlled Trial/Cluster Randomised Controlled Trial
- TB
- Tuberculosis
- TCS
- Trial Steering Committee
- TMU
- Trial Management Unit
- WHO
- World Health Organization
